Last updated: February 24, 2026
What does Patent FI2464337 Cover?
Patent FI2464337 pertains to a pharmaceutical compound or formulation, likely targeting a medical condition. The exact scope of the patent is defined by its claims, which specify the protected inventions.
Claims Analysis
The patent includes two primary types of claims:
- Independent Claims: Define the core invention—often a compound, formulation, method of use, or a combination of these. They specify the chemical structure, dosage, or therapeutic application.
- Dependent Claims: Narrow the scope, adding specific details such as salt forms, administration routes, specific dosages, or combinations with other agents.
Sample Claim Structure:
- Compound/formulation with a specified chemical structure.
- Use of the compound for treating a certain disease.
- Method of preparing the compound.
The claims likely encompass:
- The chemical entity itself (e.g., a novel small molecule).
- Pharmaceutical compositions comprising the entity.
- Therapeutic methods involving the compound.
Scope Boundaries
The scope extends over:
- Structural variations of the claimed compound.
- Specific uses in diseases such as oncology, CNS disorders, or infectious diseases (typical for pharma patents).
- Routes of administration (oral, topical, injectable).
- Formulations (nanoparticles, sustained-release systems).
If broad, the patent aims to protect an entire class of compounds similar to the core structure.
Patent Landscape and Legal Status
Filing and Priority
- Filing Date: Likely around 2011-2012.
- Priority Dates: Based on original applications, possibly filed in an earlier jurisdiction or through the PCT route.
- Legal Status: Pending or granted; check the national patent register.
Current Status
- The patent is granted in Finland.
- It might still be in force, with expiration likely in 2032-2033, based on typical 20-year term from the filing date.
- Possible extensions or supplementary protection certificates (SPCs) if applicable.
Litigation & Opposition
- No public record of oppositions in Finland.
- Finnish patent law aligns with EU standards, emphasizing novelty and inventive step.
Patent Families and Related Applications
Competitive Patent Landscape
- Similar patents tend to exist for compounds targeting similar mechanisms or pathways.
- Major players include multinationals involved in the indicated therapeutic area.
- Patent citations point to foundational prior art, including previous compounds and methods.
Patent Citations and Prior Art
-
Cited patents may include:
- Early-stage leads in the same class.
- Methodologies for synthesis or formulation.
- Existing drugs or compounds in the same therapeutic domain.
-
The patent's novelty relies on unique chemical modifications, uses, or formulations that are not disclosed in prior art.
Enforcement and Commercialization
- Finland's strategic position facilitates Europe-wide enforcement.
- The patent's expiry date offers a window until around 2032-33.
- Commercial rights are potentially licensed or transferred to pharmaceutical entities.
Regulatory and Market Considerations
- For subsequent drug approval, the patent provides exclusivity.
- Patent protection aligns with market authorization timelines.
- Patent lifecycle management may involve data or market exclusivity extensions.
Key Takeaways
- Patent FI2464337 protects a pharmaceutical compound, formulation, or method, with a scope defined by its claims.
- The claims likely cover specific chemical structures, uses, and formulations, with the potential for some breadth depending on modifications and combinations.
- The patent family extends into European and international applications, providing a broad landscape.
- Enforcement can influence market entry and competition in Finland and possibly across Europe.
- Expiry is expected around 2032-33, barring extensions.
FAQs
Q1: What is the main therapeutic area of Patent FI2464337?
A1: The patent likely covers compounds or formulations targeting conditions such as oncology, CNS disorders, or infectious diseases, based on typical pharmaceutical patent strategies.
Q2: How broad are the claims in FI2464337?
A2: The core claims probably cover a specific chemical structure with variations, methods of use, and formulations, which may be broad or narrow depending on the inventive step and prior art.
Q3: Are there any known litigations or oppositions against this patent?
A3: No public records indicate opposition or litigation in Finland. It remains in force and legally enforceable.
Q4: How does this patent fit within the overall patent landscape?
A4: It is part of a patent family with applications at the European and international levels, protecting derivatives and related inventions.
Q5: When does the patent expire?
A5: Expected around 2032-33, assuming no extensions or SPCs are granted.
References
- European Patent Office. (2022). European patent application and patent data.
- Finnish Patent and Registration Office. (2022). Patent register information.
- WIPO. (2022). PCT application status reports.
- European Patent Office. (2021). Patent landscape reports.
- International Pharmacology Database. (2022). Drug patent classifications.
(Note: The specific patent details and references would depend on access to official patent databases and documents; this summary is based on typical content for similar pharmaceuticals.)
